Background and Aims: Data on the interaction of cardiovascular disease (CVD) risk factors and obstructive sleep apnea (OSA) in the pathogenesis of CVD are limited. We examined the cross-sectional associations and interactions between OSA, CVD risk factors and CVD in a large sleep clinic cohort.
posite of heart failure, coronary and cerebrovascular disease) at presentation. We determined the odds ratio (OR) of CVD between patients with and without severe OSA [apnea-hypopnea index (AHI)>30 vs AHI < 30]. To assess the interaction between OSA and CVD risk factors (hypertension, diabetes and dyslipidaemia), ORs of CVD for patients with AHI < 30 with (+) the risk factor, AHI>30 without (-) the risk factor, and AHI>30+the risk factor were referenced to patients with AHI < 30-the risk factor.
Results: The OR for CVD in patients with severe OSA was 1.44 (95% CI 1.17-1.78, P = 0.0006). In the absence of severe OSA, each risk factor increased the OR for CVD (see Table) . Compared to patients without severe OSA, those with severe OSA had greater CVD risk when there was co-existing hypertension, but not with co-existing diabetes or dyslipidemia.
Conclusion:
The crude ORs for CVD are increased in patients with severe OSA and patients with CVD risk factors. Severe OSA amplified this risk in patients with hypertension, but not diabetes or dyslipidaemia. The influence of other co-variates will be modelled. increases the risk of cardiovascular events, such as hypertension and ischemic heart disease (IHD). Patients with heart failure (HF) are at higher risk for sleep disorder; however, there is no documentation on NASD's association with HF to date. Therefore, our study aimed to determine whether NASD increases the risk of incident HF.
Methods: Using the outpatient and inpatient data from Taiwan's Longitudinal Health Insurance Database, we conducted a nationwide cohort study of patients with a first-time diagnosis of NASD in the year 2000 and followed up the risk of incident heart failure until December 31, 2013. We calculated risks and incidence ratios of HF for patients with NASD compared with the general population. The cumulative incidence of NASD and the subsequent risk of HF are assessed by the Kaplan-Meier method and Cox regression using a matched comparison cohort of HF patients without NASD.
Results: The NASD cohort had an adjusted hazard ratio (HR) of incident HF 23.6% higher than that of the cohort without NASD (95% CI = 1.164-1.308; P < 0.001). In the NASD population, the mean interval to HF in males and females were 5.02 AE 3.65 years and 5.02 AE 3.70 years, respectively. The Kaplan-Meier analysis indicated that after the seventh year, the incidence of HF was higher in the NASD cohort than in the control cohort till the end of the follow up. Results: Gene expression levels of miR-21-5p (adjusted P = 0.024) and miR-23-3p (adjusted P = 0.028) were significantly decreased in treatment-naïve OSA patients as compared with that in PS subjects, while TNF-α gene expression (adjusted P = 0.04) was significantly increased. Gene expression levels of both miR-21-5p, and miR-23-3p were negatively correlated with apnea hypopnea index (r = −.478, P < 0.001; r = −.446, P = 0.001) and oxygen desaturation index (r = −.45, P = 0.001; r = −.421, P = 0.001), while TNF-α gene expression was positively correlated with apnea hypopnea index (r = 0.388, P = 0.003). in vitro IHR treatment result in a significant decrease of miR-21-5p, miR-23-3p, and miR-155-5p gene expressions as compared with normoxic condition, but a significant increase of miR-146b-5p, TLR2, TLR6, TNF-α, HIF-1α, and HIF-2α gene expressions (all P values < 0.05). Both miR-21 5p and miR-23-3p gene expressions were negatively correlated with gene expressions of TLR2, TNF-α, and HIF-2α, and positively correlated with miR-155-5p gene expression. MiR-146a-5p gene expression was positively correlated with both TLR6 and HIF-1α gene expressions.
MiR-21-5p and miR-23-3p were down-regulated both in severe OSA patients and with in vitro IHR stimuli, while TNF-α was upregulated. These findings provide biological insight into mechanisms by which IHR-suppressed miRs potentiate cell apoptosis and inflammation, and indicate that overexpression of the miR-21/miR-23 could represent a potential therapy for OSA.
